Results 261 to 270 of about 8,253,745 (359)

Early hyperaesthesia and late hypoaesthesia as manifestations of sensory neuropathy in dentistry - two case reports. [PDF]

open access: yesFront Endocrinol (Lausanne)
Lipták L   +10 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

Of Women, By Women, and For Women

open access: yesJACC: Case Reports, 2019
Julia Grapsa, MD, PhD   +1 more
doaj   +1 more source

The diagnosis dilemma of coexistence of neurosarcoidosis and tuberculosis: case reports and literature review. [PDF]

open access: yesFront Med (Lausanne)
Sun Q   +9 more
europepmc   +1 more source

Cavernous Sinus Cavernoma Treated with Radiation Therapy —Case Report—

open access: bronze, 1994
Masaharu Maruishi   +5 more
openalex   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

<i>Globicatella sanguinis</i>-A Literature Review of Case Reports. [PDF]

open access: yesMedicina (Kaunas)
Rîpă CV   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy